The latest price target for Longboard Pharmaceuticals (NASDAQ:LBPH) was reported by Baird on July 11, 2024. The analyst firm set a price target for $60.00 expecting LBPH to rise to within 12 months (a possible 66.90% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Longboard Pharmaceuticals (NASDAQ:LBPH) was provided by Baird, and Longboard Pharmaceuticals maintained their outperform rating.

There is no last upgrade for Longboard Pharmaceuticals

There is no last downgrade for Longboard Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Longboard Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Longboard Pharmaceuticals was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.

While ratings are subjective and will change, the latest Longboard Pharmaceuticals (LBPH) rating was a maintained with a price target of $36.00 to $60.00. The current price Longboard Pharmaceuticals (LBPH) is trading at is $35.95, which is out of the analyst’s predicted range.